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Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive neoplasm characterized by a marked fibroinflammatory microenvironment 1 , the presence of which can promote both cancer induction and growth [2] [3] [4] . Therefore, selective manipulation of local cytokines is an attractive, although unrealized, therapeutic approach. T cells possess a unique mechanism of p38 mitogen-activated protein kinase (MAPK) activation downstream of T cell receptor (TCR) engagement through the phosphorylation of Tyr323 (pY323). This alternative p38 activation pathway is required for proinflammatory cytokine production 5, 6 . Here we show in human PDAC that a high percentage of infiltrating pY323 + T cells was associated with large numbers of tumor necrosis factor (TNF)-− and interleukin (IL)-17-producing CD4 + tumor-infiltrating lymphocytes (TILs) and aggressive disease. The growth of mouse pancreatic tumors was inhibited by genetic ablation of the alternative p38 pathway, and transfer of wild-type CD4 + T cells, but not those lacking the alternative pathway, enhanced tumor growth in T cell-deficient mice. Notably, a plasma membrane-permeable peptide derived from GADD45-, the naturally occurring inhibitor of p38 pY323 + (ref. 7) , reduced CD4 + TIL production of TNF-, IL-17A, IL-10 and secondary cytokines, halted growth of implanted tumors and inhibited progression of spontaneous KRAS-driven adenocarcinoma in mice. Thus, TCR-mediated activation of CD4 + TILs results in alternative p38 activation and production of protumorigenic factors and can be targeted for therapeutic benefit.
A hallmark of PDAC is a fibro-inflammatory microenvironment that is a major source of tumor-promoting cytokines and chemokines that cause angiogenesis, metastasis, resistance to chemotherapeutic agents and escape from host defenses [8] [9] [10] . Consistent with this, antiinflammatory drug treatment of mice with PDAC has been shown to reduce the development of precancerous lesions, tumor vascularization, and cancer growth 11, 12 . Infiltrating T cells are a prominent feature of the inflammatory microenvironment and can be a source of tumor-promoting cytokines [2] [3] [4] . Because the p38 alternative activation pathway is upstream of many such T cell cytokines 6, 13 , its involvement in human PDAC was evaluated. Pancreatic tissues were collected from 192 histologically classified primary PDAC patients that had not had neoadjuvant therapy at the time of surgery and were analyzed for infiltrating p38 pY323 + T cells. In all samples, we found infiltration of T cells that stained with antibodies to p38 pY323. Histological examination of sequential serial sections revealed the presence of CD3 + T cells expressing both p38 pY323 and TNF-α ( Supplementary  Fig. 1a ). Triple-immunofluorescence staining revealed the presence of p38 pY323 + cells that expressed both TNF-α and IL-17A (Fig. 1a) . Enumeration of the percentage of pY323 + TILs allowed us to segregate patients into two groups using receiver operating characteristic (ROC) analysis: those with <10% (mean: 4.3%) CD3 + pY323 + TILs (n = 153, ~80%) and those with ≥10% (n = 39, mean: 15.5%) (Fig. 1b) . Of note, although there was no difference in the degree of CD3 + T cell infiltration between the two groups (Fig. 1b) , the percentage of TNF-α-, IL-17A-and IL-21-producing CD4 + T cells was much higher in the subset of patients with ≥10% p38 pY323 + T cells ( Fig. 1c and Supplementary Fig. 1b) . The expression of the T H 17 transcription factor Rorc and the proangiogenic factor Vegf (a factor downstream of TNF-α and IL-17A) (Fig. 1d) , and correspondingly, the density of CD31 + tumor vessels, which is associated with poor prognosis 14 (Fig. 1e) , were increased in the group with high levels of p38 pY323 (p38 pY323-high). However, expression of Gata3, Tbet and Foxp3, which encode T helper cell and regulatory T cell transcription factors, was similar between the two groups ( Supplementary Fig. 1c) . Recent studies have shown that PDAC can be subclassified on the basis of tumor plasticity, in which cells with an epithelial phenotype change toward those with a mesenchymal phenotype, also known as an epithelial-mesenchymal transition (EMT). These cells lose epithelial markers (such as cytokeratin 19) and acquire mesenchymal markers (such as α-smooth muscle actin, vimentin and desmin) and factors that promote EMT (sonic hedgehog, snail, CCL20 and leptin) 15, 16 . We found no differences Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression l e t t e r s 1 3 3 8 VOLUME 21 | NUMBER 11 | NOVEMBER 2015 nature medicine in EMT markers between the two groups ( Supplementary Fig. 1d ). Notably, patients having infiltrates with ≥10% p38 pY323 + T cells had a statistically significantly poorer prognosis (median survival 9.8 months; 5.3% 5-year survival) as compared to patients with <10% p38 pY323 + (median survival 20.3 months; 16.1% 5-year survival) (Fig. 1f) . No correlations with other clinical or pathological findings (such as age, gender, tumor size, TNM classification stage, histological grading, status of resection margin or number of tumor-positive lymph nodes) were found (Supplementary Table 1 ). Multivariate Cox-regression analysis confirmed that the prevalence of p38 pY323 + TIL is an independent prognostic marker for PDAC (Supplementary Table 2 ). After patients with incurable disease at the time of surgery (such as those with liver metastases or residual macroscopic cancer) were excluded, CD4 + T cell p38 pY323 status remained an independent prognostic factor (Supplementary Table 3 ). The finding that p38 pY323 + CD4 + TILs are a feature of aggressive human PDAC prompted us to investigate how the T cell p38 alternative pathway affects tumor progression by using two different mouse models of pancreatic cancer. We injected Panc02 pancreatic tumor cells subcutaneously into the flanks of wild-type (WT) mice or animals in which the Tyr323 residues in p38-α and p38-β were replaced with phenylalanines (hereafter referred to as double knock-in, or DKI, mice). The latter have intact stress-induced, but not TCR-induced, p38 activity and have diminished TCR-induced production of proinflammatory cytokines in vitro and in vivo 13 . Notably, Panc02 tumors in DKI mice had reduced volume and weight as compared to those in WT animals (Fig. 2a) . This was not due to decreased T cell infiltration (Supplementary Fig. 2a ) or CD4 + T cell activation, as assessed by cell-surface expression of CD44 and CD69 (Supplementary Fig. 2b ). However, many more WT CD4 + TILs produced TNF-α than did DKI CD4 + TILs (Fig. 2b) . In addition, the number of CD4 + TILs producing IL-10, another tumor-promoting cytokine 17 , was lower in DKI mice (Fig. 2b) . We observed that WT and DKI mice had small, and similar numbers of T cells producing IFN-γ at low levels and that IL-17A was found at very low levels in CD4 + TILs from mice of both genotypes. TNF-α production is downstream of the activity of the transcription factor IRF4 (ref. 18 ), which itself is downstream of alternative p38 activation 6 , and there was a corresponding reduction in IRF4 expression in DKI CD4 + TILs ( Supplementary  Fig. 2c ). The percentage of TNF-α-producing CD8 + TILs from WT mice was lower than CD4 + TILs and was further modestly reduced in DKI mice (Supplementary Fig. 2d) . Notably, TNF-α production by tumor-infiltrating macrophages, B cells, granulocytes and myeloidderived suppressor cells was similar in WT and DKI mice (Supplementary Fig. 2e ). DKI CD4 + TILs that were stimulated via the TCR produced less TNF-α than WT TILs, whereas the responses of both to treatment with phorbol myristate acetate (PMA) and ionomycin were similar (Supplementary Fig. 2f ). To determine whether T cell-mediated enhancement of tumor growth was in fact due to CD4 + T cell-derived TNF-α, we adoptively transferred CD4 + T cells from WT or Tnf −/− mice to TCR α-chain-knockout (Tcra −/− ) mice, and 10 d later we subcutaneously injected Panc02 cells. Despite equivalent T cell engraftment (Supplementary Fig. 3a) , tumors grew more rapidly in recipients of the WT T cells as compared to those of the Tnf −/− T cells (Fig. 2c) . Adoptive transfer of CD4 + -but not of CD8 + , WT or DKI-T cells into Tcra −/− hosts followed by tumor cell inoculation showed that the differences in tumor growth were intrinsic to CD4 + T cells ( Fig. 2d and Supplementary Fig. 3b ). In addition to its direct effects on tumor cell growth and viability, TNF-α induces the expression of cytokines and chemokines with protumorigenic activity from tumor cells 19 . Consistent with a decrease in TNF-α production by CD4 + TILs, tumor cells from DKI mice had markedly reduced expression of Ccl2, which induces tumor cell migration and neoangiogenesis, and the proangiogenic factor Vegf, whereas expression of Ccl5 and Tgfb1 was unaffected (Fig. 2e) . Correspondingly, although T cell infiltration was similar, the density of tumor microvessel formation, as indicated by CD31 staining, was reduced in DKI tumors as compared to that in WT tumors (Fig. 2f) . Panc02 cells express TNF receptor (TNFR) 1 and TNFR2 (data not shown). Because TNF-α directly induced Ccl2 and Vegf in Panc02 cells in vitro (Fig. 2g) , and TNF-α production was only elevated in infiltrating T cells ( Fig. 2b and Supplementary Fig. 2e ), we propose that expression of Vegf and Ccl2 in vivo was in response to T cell-derived TNF-α. We examined a second tumor model using KPC mice that express mutated KRAS in pancreatic epithelium and, when heterozygous for Trp53 (encoding p53), develop spontaneous tumors that closely npg mimic the human disease (including pancreatic intraepithelial neoplasia (PanIN) precursor lesions and progression to fully developed carcinoma 20 ) starting at approximately 8-10 weeks of age. In regions rich in infiltrating T cells, we easily detected CD3 + mononuclear cells that stained for both p38 pY323 and TNF-α, which were absent in T cell-deficient regions ( Fig. 2h and Supplementary Fig. 3c ; isotype control in Supplementary Fig. 3d ). To test the possibility that alternative p38 activation was involved in oncogene-driven tumorigenesis, we lethally irradiated 6-week-old KPC mice and reconstituted them with WT or DKI bone marrow. The former developed invasive cancer and had a median survival of 28 d (mean survival of 37 ± 9 d), whereas mice that received DKI bone marrow survived much longer (median survival 84 d, mean survival 80 ± 16 d) (Fig. 2i) . Therefore, the p38 alternative pathway promotes tumor progression in orthotopic and genetic models of murine pancreatic cancer, in agreement with the finding that large numbers of p38 pY323 + TILs in human cancer are associated with aggressive disease. On the basis of the genetic evidence that ablating the T cell-restricted p38 alternative pathway impairs tumor-promoting cytokine production, we developed a selective inhibitor of this pathway. GADD45-α binds p38 and inhibits the activity of pY323 (alternatively activated) but not of pT180 and pY182 (classically activated) p38 (ref. 7) . To determine the minimum p38-interacting fragment, GADD45-α residues 71-96 (which bind p38 (ref. 21); referred to hereafter as GADD45-α 71-96 ) and overlapping subregions were fused to glutathione S-transferase (GST), and these fusion proteins were used to pull down recombinant p38. GST-GADD45-α 71-96 pulled down p38 as did GST-GADD45-α 71-85 , whereas GST-GADD45-α 81-96 could not (Fig. 3a) . In agreement, a GST fusion protein with GADD45-α in which amino acids 71-80 were deleted (GST-GADD45-α∆10) bound p38 poorly (Fig. 3b) . GST-GADD-45-α and GST-GADD45-α 71-85 completely blocked phosphorylation of the p38 substrate ATF2 by tyrosine kinase ZAP70-activated (i.e., alternatively activated) p38, whereas GST-GADD45-α∆10 had no effect (Fig. 3c) . Importantly, neither GADD45-α nor its fragments affected phosphorylation of ATF2 by MAPK kinase 6 (MKK6)-activated (i.e., classically activated) p38. Thus, the highly conserved GADD45-α residues 71-85 specifically inhibit the activity of p38 pY323.
The addition of multiple arginine residues can promote cellular uptake of proteins as large as ~50 kDa (refs. 22,23) . We created a recombinant molecule containing 11 N-terminal arginines followed by GADD45-α fragment 71-85 (referred to as (11R)-GADD45-α 71-85 ), which was still able to inhibit ZAP70-activated p38 (Fig. 3d) . The uptake and longevity of FITC-labeled (11R)-GADD45-α 71-85 was measured by flow cytometry (Fig. 3e) . After a 2-h incubation, all of the cells were FITC-bright, with the signal decaying over the next 24-48 h. The ability of (11R)-GADD45-α 71-85 to inhibit p38 activation in T cells was determined by the phosphorylation of ATF2, a substrate common to both the alternative and classical pathway. npg (11R)-GADD45-α 71-85 inhibited the phosphorylation of p38 in T cells stimulated with antibodies to CD3 and CD28 but not those stimulated with PMA and ionomycin (Fig. 3f) . (11R)-GADD45-α 71-85 treatment inhibited T cell proliferation induced by antibodies specific to CD3 and CD28 in a dose-dependent manner, but it had no effect on B cells (Fig. 3g) , which lack the alternative pathway 5 . (11R)-GADD45-α 71-85 treatment inhibited T cell proliferation induced by antibodies specific to CD3 and CD28 over a range of stimulatory concentrations (Fig. 3h) without affecting cell viability ( Supplementary  Fig. 4 ), but it did not inhibit PMA plus ionomycin-induced T cell proliferation (Fig. 3h) . (11R)-GADD45-α 71-85 -treated CD4 + T cells produced much less TNF-α than controls in response to stimulation with antibodies specific to CD3 and CD28, with the inhibition being similar to that caused by the p38 catalytic inhibitor SB203580 (Fig. 3i) . In contrast, whereas SB203580 inhibited TNF-α induced by PMA plus ionomycin, (11R)-GADD45-α 71-85 treatment had no effect. Thus, (11R)-GADD45-α 71-85 treatment targets alternatively but not classically activated p38. Notably, (11R)-GADD45-α 71-85 treatment had no effect on T H 1 or cytotoxic T cell (CTL) effector function, as measured by IFN-γ production by T H 1-skewed CD4 + T cells and by CD8 + CTL degranulation and production of IFN-γ, respectively ( Supplementary Fig. 5a,b) .
To test the therapeutic potential of (11R)-GADD45-α 71-85 , WT mice were inoculated with Panc02 subcutaneously and tumors were allowed to grow for 14 d. The tumors were injected with (11R)-Scrambled ((11R)-Scr, a peptide containing the same amino acids as in the GADD45-α 71-85 fragment but in a random order), (11R)-GADD45-α 71-85 or water three times a week. Whereas tumor growth progressed in mice treated with the controls, it was inhibited by treatment with (11R)-GADD45-α 71-85 (Fig. 4a) . The specificity of (11R)-GADD45-α 71-85 was confirmed by the finding that it had no effect on tumor growth in DKI mice ( Supplementary  Fig. 6a ). Histopathological analysis showed less vascularization (by CD31 staining) in (11R)-GADD45-α 71-85 -treated tumors (Fig. 4b) .
In agreement with the findings in DKI mice, CD4 + TILs from (11R)-GADD45-α 71-85 -treated tumors produced less TNF-α than those from control-treated animals, whereas the amount of IFN-γ was relatively unaffected (Supplementary Fig. 6b ). (11R)-GADD45-α 71-85 by itself had no effect on Panc02 growth and viability in vitro ( Supplementary  Fig. 6c ), and we found no elevation of tumor cell apoptosis or necrosis in histological examination of the tumors ( Supplementary  Fig. 6d,e) . Consistent with (11R)-GADD45-α 71-85 having a cytostatic effect, tumors in (11R)-GADD45-α 71-85 -treated mice resumed growth when administration of the peptide ceased (Fig. 4a) . Notably, there was no toxicity associated with (11R)-GADD45-α 71-85 treatment, as judged by the health and weight of the mice, and the normal serum levels of intracellular enzymes that are released by tissue damage, such as alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, amylase and lactate dehydrogenase (Supplementary Fig. 6f ).
We next treated KPC mice with (11R)-GADD45-α 71-85 or (11R)-Scr starting at 9 weeks of age and evaluated the pancreas 3.5 weeks later. The area of intrapancreatic fibro-inflammatory reaction was reduced in the (11R)-GADD45-α 71-85-treated mice as compared to the (11R)-Scr-treated mice (Fig. 4c) , and the area of normal pancreas was higher in the former (Fig. 4d) . Correspondingly, (11R)-GADD45-α 71-85 treatment slowed progression from early PanIN to late PanIN lesions (PanIN3, carcinoma in situ) and adenocarcinoma but not initiation (early PanIN lesions), and was associated with reduced acinar-to-ductal metaplasia (ADM) that did not, however, reach statistical significance (Fig. 4d) . Eight of 16 mice treated with (11R)-Scr developed PDAC, five of which died during the course of treatment owing to progressive cancer (31.2%) (Supplementary Table 4) . In contrast, only 14.2% (2 of 14) of mice treated with (11R)-GADD45-α 71-85 developed PDAC, one of which died (7.1%). Pancreata from KPC mice treated with (11R)-GADD45-α 71-85 had statistically significant reductions in the numbers of CD4 + T cells expressing TNF-α, the T H 17 transcription factor ROR-γt, IL-17A and IL-10 as compared to those from control mice, with the number of cells expressing IFN-γ being only slightly reduced ( Fig. 4e; the gating strategy is shown in Supplementary  Fig. 6g ). In line with reduced TNF-α, (11R)-GADD45-α 71-85 treatment decreased Irf4 and Rorc mRNA expression in CD4 + TILs (Supplementary Fig. 6h ). To investigate the particular effector T helper cell types secreting TNF-α and affected by treatment with (11R)-GADD45-α 71-85 , we stained TILs from KPC mice for TNF-α and the T H type-specific transcription factors GATA3 and ROR-γt. Although we observed a small percentage of TNF-α-producing T H 2 and T H 17, neither of these were major TNF-α producers (Supplementary Fig. 6i ). (11R)-GADD45-α 71-85 treatment also inhibited factors downstream of TNF-α such as Ccl2, Ccl5, Vegf and Tgfb1 in pancreatic cells (Fig. 4f) . Treatment of KPC mice was begun at 9 weeks of age, when the pancreas was expected to be mostly normal. To test whether (11R)-GADD45-α 71-85 treatment could affect pre-existing tumors, we conducted a survival study using mice with verified pancreatic tumors. KPC mice in which tumors were confirmed by ultrasound (tumor volumes 100-150 mm 3 ) were randomized into two groups, with one receiving (11R)-GADD45-α 71-85 and the other (11R)-Scr intravenously (i.v.) three times a week. There was a clear and statistically significant difference in survival between these groups, with the control (11R)-Scr-treated mice living a median of 10 d (mean survival 12 ± 3 d) and the (11R)-GADD45-α 71-85 -treated mice a median of 20 d (mean survival 22 ± 4 d) (P < 0.05) (Fig. 4g) . The effect of (11R)-GADD45-α 71-85 treatment on production of proinflammatory factors in the established tumors was determined after three injections. As with the previously described prevention model, there was a reduction in the percentage of CD4 + TILs producing TNF-α, ROR-γt and IL-17A, and IFN-γ production was decreased in both CD4 + and CD8 + TILs ( Supplementary  Fig. 7a,b) . Of note, treatment with (11R)-GADD45-α 71-85 increased the ratio of CD8 + to CD4 + T cells in the tumor, an observation that has been associated with decreased disease (Supplementary Fig. 7c) 24, 25 . These results support the possibility that inhibition of the alternative p38 pathway could be useful as both a neoadjuvant (preoperative) therapy and an adjuvant therapy.
Nearly all solid tumors have infiltrating immune cells that are unable to eliminate the tumor and, in many cases, paradoxically promote tumor progression by creating a microenvironment with features of chronic inflammation [2] [3] [4] 10, [26] [27] [28] . One tumor-promoting cytokine in the micromilieu is TNF-α, and anti-TNF-α therapies have been beneficial in treating cancer 29, 30 . In addition, it was recently shown that T H 17 cells enhanced the progression of PanIN 31 , supporting the notion that T cells are promising targets in inflammatory cancers. Given its central role in cytokine production, one might expect that inhibiting p38 would be beneficial in inflammatory diseases or cancers 32 . However, to date all selective p38 catalytic inhibitors have failed owing to side effects such as liver toxicity, presumably because of off-target activities or the effects of global p38 inhibition 33 . The latter might be avoided if one could specifically target p38 in T cells. Here, inhibition of T cell-derived inflammatory cytokines with a cell membrane-permeable GADD45-α-derived peptide inhibited neoangiogenesis, PanIN and PDAC progression. Many of the protumorigenic factors in the neoplastic milieu (such as CCL2, CCL5, VEGF, and TGF-β1) are not T cell derived 2, 4, 19, 34 , and it is therefore notable that specific inhibition of p38 in T cells resulted in their decline. This indicates that infiltrating T cells may orchestrate the production of tumor-promoting factors from cells other than T cells, even from tumor cells themselves.
Therapeutic strategies are moving toward 'personalized oncology' , the targeting of often-complex differences in the molecular bases for tumor initiation and progression between individuals. In this regard, we found that the presence of a high percentage of p38 pY323 + TILs is a very strong negative prognostic factor in human PDAC, and that interference with this pathway in mouse PDAC was beneficial in both preventive and treatment models. Therefore, interference with the p38 alternative pathway using selective compounds such as (11R)-GADD45-α 71-85 may be of particular benefit to patients with high levels of p38 pY323 + TILs. A potential advantage of targeting the T cell p38 alternative pathway in the tumor microenvironment, rather than a single cytokine or factor, is that it interferes with multiple downstream proinflammatory events that are involved in tumor progression.
MeTHoDS
Methods and any associated references are available in the online version of the paper. Panc02 cells. The mouse pancreatic cancer B6 cell line Panc02 (mycoplasmafree) was grown in RPMI containing 10% FCS supplemented with penicillinstreptomycin and l-glutamine (complete medium) at 37 °C in 5% CO 2 .
T cell purification. T cells were purified using mouse T cell recovery column kits (Cedarlane). For positive selection of CD4 + T cells, mouse CD4 + T cell isolation kit II was used (Miltenyi).
In vitro T cell assays. 5 × 10 4 purified T cells in 200 µl (proliferation) or 5 × 10 5 purified T cells in 2 ml (western blotting) of complete medium were stimulated with either plate-bound anti-CD3 (2 µg/ml) and anti-CD28 (2 µg/ml) or PMA (10 ng/ml) and ionomycin (1 µg/ml) for 48 h. To measure proliferation, [ 3 H]thymidine was added, and the cells were harvested 16 h later. Cell culture supernatants were collected after 48 h, and TNF-α was detected by ELISA (Ready-Set-Go kit, eBiosciences).
Adoptive transfer. For adoptive transfer experiments, CD4 + or CD8 + T cells were isolated from spleens and lymph nodes of WT, DKI and Tnf −/− donor mice to more than 90% purity. 2.5 × 10 6 cells/300 µl PBS were injected into the tail veins of recipient mice. After 10 d, 7.5 × 10 5 Panc02 cells were inoculated in the left flank and tumor growth was monitored. Tumor size and burden did not exceed that allowed by the NCI protocol.
Protein expression and purification. p38-α, MKK6 and GADD45-α proteins were expressed in the bacterial strain BL21(DE3) using the vectors pGEX-4T-1 or pET15b. The 10-amino acid internal deletion mutation of GADD45-α (GADD45α∆71-80) was generated by site-directed mutagenesis using the QuikChange kit (Stratagene). For the synthesis of small peptide fragments of GADD45-α, oligonucleotides were synthesized, annealed and ligated to the pGEX-4T-1 vector. After plasmid transformation, single colonies were grown in culture and, after reaching an absorbance at 600 nm (A 600 ) of 0.5-1.0, protein expression was induced with 0.5 mM isopropyl β-d-thiogalactopyranoside. Cultures were further incubated at 14 °C overnight. Cells were resuspended in PBS (including 0.5 M NaCl for His-tagged proteins), 0.1% Triton X-100 and 1 mM phenylmethylsulfonyl fluoride, sonicated and centrifuged at 20,000g at 4 °C for 20 min. His-tagged proteins were purified with cobaltcharged chelating-Sepharose Fast Flow beads and eluted with 0.3 M imidazole in PBS with 0.5 M NaCl. GST-tagged proteins were purified with glutathionesepharose Fast Flow beads and eluted with 50 mM Tris, pH 8, containing 20 mM glutathione. Proteins were concentrated and washed in PBS using Microcon YM-30 spin columns (Millipore).
Protein pulldowns. Recombinant p38 was incubated with GST beads coated with FL GADD45-α or its fragments in PBS at 37 °C for 1 h, at which time beads were washed with PBS and analyzed for p38 and GST levels by western blot using antibodies against p38 and GST.
In vitro kinase (IVK) assays. Recombinant p38 was activated with ZAP70 or MKK6 at 30 °C for 1 h or left unactivated in IVK buffer (20 mM Tris, pH 7.5, 10 mM MgCl 2 , 2 mM dithiothreitol, 5 mM β-glycerophosphate, 5 mM NaF and 0.2 mM Na 3 VO 4 ). After 1 h, full-length (FL) GADD45-α, the peptide fragment consisting of residues 71-85 (GADD45-α 71-85 ), the 10-amino acid GADD45-α internal deletion (GADD45-α∆71-80) or the 11R-fused peptides were added at the indicated concentrations and incubated at 30 °C for another 20 min. ATF-2 was added for a final 30 min in the presence of 10 µCi [γ-32 P]ATP.
LCMV infection and CTL assay. Lymphocytic choriomeningitis virus (LCMV)
Armstrong 53b was grown in baby hamster kidney cells, and viral titers were determined 35 . B6 mice were infected intraperitoneally (i.p.) with 2 × 10 5 plaque-forming units (p.f.u.) and splenocytes were harvested at day 8. Cells were treated as indicated and stimulated with LCMV gp33 and gp276 for 5 h in the presence of 1 µM monensin. Cells were stained for CD107a and IFN-γ and analyzed by flow cytometry.
Bone marrow chimeras. 6-week-old KPC mice were treated with oral antibiotics for 1 week and then irradiated with 9 Gy. Mice were reconstituted with 10 7 T cell-depleted (Dynabeads, Invitrogen) bone marrow cells from WT or DKI mice.
Isolation and stimulation of TIL, tumor cells, pancreas infiltrating T cells and pancreatic cells.
Panc02 tumors or pancreata were explanted and minced into 1-to 2-mm pieces followed by incubation in HBSS (Gibco) containing DNAse I (Roche) and Liberase (Roche) for 30 min, and pressed once through a 70-µm strainer and twice through a 40-µm strainer (BD Falcon) to create single-cell suspensions. 10 6 cells were cultured in monensin alone or together with PMA and ionomycin or with anti-CD3-and anti-CD28-coated plates at 37 °C for 4 h. Some mice were injected with Brefeldin A (0.25 mg in 0.5 ml of PBS) 6 h before harvesting and intracellular staining for cytokines. CD4 + T cells from singlecell suspensions of Panc02 tumors or KPC pancreata were isolated using CD4 + positive selection. In some experiments, Panc02 cells from established tumors or pancreatic cells from KPC mice were isolated by pressing through a 70-µm strainer followed by Lympholyte M gradient centrifugation.
Flow cytometry. 10 6 cells were incubated with anti-FcR and cell-surface staining was performed with the indicated antibodies for 30 min on ice. For intracellular npg staining, cells were washed in FACS buffer (1% BSA plus 0.1% sodium azide in PBS), fixed and permeabilized with Cytofix/Cytoperm solution for 25 min on ice followed by washing in Perm/Wash solution (BD Biosciences). Cells were stained for an additional 30 min at room temperature with the indicated antibodies. All antibodies were used at a dilution of 1:100. Panc02 tumor cells were stained with a goat anti-mouse TNFR1 followed by FITC-labeled goat-specific secondary antibody. In all experiments, cell survival was determined with Aqua or UV live-death fixable stain. Apoptosis was detected in some experiments by staining with PE and annexin V. Flow cytometry was performed using an LSRII with FACSDiva software (BD Biosciences), and data were analyzed with FlowJo 9.2 software (TreeStar).
Real-time PCR. Total RNA was isolated using Qiagen RNeasy Kits and was reverse-transcribed using Omniscript RT kit (Qiagen) according the manufacturer's instructions.
Power SYBR Green premix (Applied Biosystems) was used for quantitative PCR. All data were normalized to HPRT (hypoxanthine-guanine phosphoribosyl transferase) RNA and are presented as expression relative to this control. The primers were:
CCL2-Fwd: 5′-CCCAATGAGTAGGCTGGAGA-3′, CCL2-Rev: 5′-TCTGG ACCCATTCCTTCTTG-3′; CCL5-Fwd: 5′-ATATGGCTCGGACACCACTC-3′, CCL5-Rev: 5′-TCCTTCGAGTGACAAACACG-3′; VEGFa-Fwd: 5′-GTG AGGTTTGATCCGCATGAT-3′, VEGFa-Rev: 5′-GACCCTGGCTTTACTG CTGTA-3′; TGFβ-Fwd: 5′-TTGCTTCAGCTCCACAGAGA-3′, TGFβ-Rev: 5′-TGGTTGTAGAGGGCAAGGAC-3′; IRF4-Fwd: 5′-GCAGCTCACTTTG GATGACA-3′, IRF4-Rev: 5′-CCAAACGTCACAGGACATTG-3′; Hprt-Fwd: 5′-AGCCTAAGATGAGCGCAAGT-3′, Hprt-Rev: 5′-TTACTAGGCAGAT GGCCACA-3′.
Gene expression analysis in human tumor tissue. Tissue samples were collected and stored in RNAlater (Ambion). Tissues were disrupted with the RiboLyser device (ThermoHYBAID, Heidelberg) in 400 µl lysis buffer from the MagnaPure mRNA Isolation Kit I containing 1% DTT (vol/wt) (Roche Diagnostics). 300 µl of the lysates were collected and mixed with 120 µl lysis buffer containing DTT. After centrifugation at 13,000 rpm for 5 min, the mix was transferred into a MagnaPure sample cartridge and mRNA was isolated with the MagnaPure-LC device using their protocol for cells. An aliquot of 8.2 µl mRNA was reverse-transcribed using AMV-RT and oligo-(dT) as the primer (First Strand cDNA synthesis kit, Roche) in a thermocycler. After termination of the cDNA synthesis, the reaction mix was diluted to a final volume of 500 µl. Primer sets optimized for the LightCycler (RAS) were developed and purchased from Search-LC GmbH (http://www.search-lc.com/). PCR was performed with the LightCycler FastStart DNA Sybr GreenI kit (RAS) according to the protocols provided in the parameter-specific kits. To control for specificity of the amplification products, a melting curve analysis was performed. The copy number was calculated from a standard curve, obtained by plotting known input concentrations of four different plasmids at log dilutions to the PCR cycle number (CP) at which the detected fluorescence intensity reached a fixed value. The calculated transcript numbers were normalized to the expression of the housekeeping gene peptidylprolyl isomerase B (Ppib). Histology and immunohistochemistry. Mouse tumors or pancreata were explanted, fixed in formalin, embedded in paraffin and sectioned into 4-µm consecutive tissue sections. Prior to antibody incubation, heat pre-treatment using citrate buffer (pH 6.1) was performed. CD3 T cells were counted in five representative 400× high-power fields (HPFs), CD31-positive vessels were counted at 200×. Quantification of PanIN was made by microscopic analysis of 80 representative pancreatic ducts in H&E-stained sections. The scoring of mouse PanIN was performed as described 36 . In addition, software-based imaging was performed and the histological features (normal pancreas, fibroinflammatory infiltrate, acinar-ductal metaplasia (ADM), early PanIN and late PanIN) were quantified. Slides were scanned at 400× using an Aperio CS scanner and stored in the Aperio svs file format, using JPEG and JPEG2000 compression in eSlide Manager (Aperio), and evaluated using ImageScope Software (Aperio). Apoptosis was detected with the ApopTag Peroxidase In situ Apoptosis Detection Kit (Millipore). The groups were coded and all histological scoring was performed in a double-blinded manner by two experienced observers. Photos were made using an AxioVison software (Zeiss). A tissue microarray containing 193 samples of pancreatic tissue from patients diagnosed with PDAC was made in the clinical routine diagnostic at the University Hospital of Heidelberg. The study was approved by the local ethics committee of the University of Heidelberg and a written informed consent of each patient was taken. The diagnosis of PDAC and the tumor stage were established according to the criteria recommended by the World Health Organization 37 and the UICC (Union for International Cancer Control)38. Primary pancreatic cancer tissues were used from patients who underwent surgical resection without any neoadjuvant therapy. The tissue was stained with an automated immunostaining system (Ventana). All infiltrated CD3-positive T cells (including tertiary lymphoid structures) were counted in five representative HPF, and the percentage of pY323-positive cells among CD3-positive cells was counted in direct serial sections of the array spots. The cutoff of 10% for the pY323-high and pY323-low group was empirically determined according to the mean values of the amount of p38 pY323-positive T cells (mean: 0-10% CD3 + pY323 + : 4.3%; mean: ≥10% CD3 + pY323 + : 15.5%). For vascular density, 10 samples of the p38 pY323-low (0-10%) and pY323-high (≥10%) groups were randomly selected and stained with anti-CD31, and the number of CD31 + vessels was counted in five representative HPF from each sample. Software-based quantification was performed as above. The study was approved by the Ethics Committee of the University of Heidelberg and a written informed consent was obtained from all of the patients. KPC mouse enrollment for treatment, monitoring and endpoints. For the prevention experiments, apparently healthy 9-week-old KPC mice of either sex were randomized into the treatment ((11R)-GADD45-α 71-85 ; 11 male, 3 female) or control ((11R)-Scr; 12 male, 4 female) group. For the treatment studies, male KPC animals were monitored by weekly palpation for the presence of abdominal masses. Mice with suspected pancreatic lesions were further evaluated by ultrasound imaging to confirm tumor presence, linear dimensions and anatomic location within the pancreas. Based on the imaging data, 3D volumes were computed for each tumor, and lesions were qualified as residing in the head of pancreas (HOP), body of pancreas (BOP) or tail of pancreas (TOP). Only tumors consistent with PDAC appearance, lacking cystic or significant inflammatory components, and measuring less than 150 mm 3 in volume were considered enrollable and assigned by a stratified randomization algorithm to npg one of two study arms using a rolling enrollment approach, based on tumor baseline volume, individual animal weight and age at enrollment. Mice with two or more distinct tumors detected in the pancreas, tumor masses detected in other sites or organs, as well as animals showing signs of biliary occlusion (such as those with an enlarged gall bladder), or overall poor health were excluded from further consideration. Mice were treated with 80 µg/200 µl of either (11R)-GADD45-α 71-85 or (11R)-Scr in PBS with 3% acetonitrile three times per week on alternate days for up to 6 weeks. Animals were monitored twice daily, and mice deemed moribund were euthanized and necropsied. The sample sizes were chosen to be sufficient to allow statistical analysis of the outcomes of the experimental versus control arms of the studies.
MTT (3-
Ultrasound. Prior to the scan, mice were shaved and a depilatory (SurgiCream, Surgi-Care) applied to remove fine hair and reduce image artifacts due to air-transducer interface. Prior to imaging, 3 ml of saline was injected i.p. to float the pancreas and improve image contrast with respect to the surrounding organs. Warm ultrasound gel was applied to reduce image artifacts at the transducer-skin interface. The acoustic focus was placed at the center of the pancreatic tumor. Images were acquired in 3D using the Vevo2100 ultrasound scanner (VisualSonics, Inc, Toronto, Canada), MS-550S transducer (40-µm axial resolution) at 40 MHz with 0.076-mm step size (image thickness). Tumor volumes were analyzed using the parallel ROI algorithm (Vevo2100 VisualSonics software).
Treatment plan, monitoring and study endpoints. Animals were dosed with 80 µg/200 µl of either experimental or control peptide (formulated in PBS, 3% acetonitrile) for 3 d per week on alternate days for up to 6 weeks. Animals were monitored twice daily for signs of deteriorating health, as indicated by weight loss, slow movement, hunched posture and hypothermia. Mice deemed morbid by the above criteria were processed by terminal blood plasma collection, followed by a full necropsy and tissue preservation for histopathologic and biomarker evaluation. Animals were imaged mid-treatment, at day 13, and, whenever possible, at day 27. Stat imaging was applied for animals that reached the study endpoint before the scheduled imaging date.
Statistical analyses. Statistics were calculated using GraphPad Prism 6.0 software with the appropriate statistical tests: two-tailed Student's t-test, onesample t-test (tumor weight, hypothetical value 100) and Wilcoxon-signed rank (MTT assay, hypothetical value 100); *P < 0.05, **P < 0.01, ***P < 0.001. SAS software (Release 9.4, SAS Institute; Cary, NC, USA) was used for survival analyses. The Kaplan-Meier method was performed to estimate survival rates and the log-rank test was used to compare survival curves statistically. For multivariate survival analysis, the Cox proportional hazards model was used to compute hazard ratios and its 95% confidence interval. ROC curves were calculated to determine the pY323 cutoff for long-term survival by using logistic regression analysis. Correlations between the two groups (pY323-high versus pY323-low) and clinical or pathological findings were analyzed by using the Fisher's exact test and the Mann-Whitney-U test. All tests were used two-sided and P < 0.05 was considered as statistically significant.
